Novartis

Lore & Background

Novartis was created in March 1996 and began operations on 20 December from the merger of Ciba-Geigy and Sandoz Laboratories, both Swiss companies. R. The name Novartis was based on the Latin terms novae artes (new skills). The plant ceased operation in 1996. A follow-up study from 1996–2000 indicated that while there were more cancer cases than expected, rates had significantly fallen and the difference was statistically insignificant. The CIA purchased quantities of LSD from Sandoz for its illegal human experimentation program MKUltra.

Reader's Guide

Novartis represents a major consolidation in the pharmaceutical industry, combining the histories and product lines of two long-established Swiss chemical and drug companies. Its formation in 1996 was the largest corporate merger up to that time, creating a global powerhouse. The company's portfolio includes blockbuster drugs such as Gleevec for cancer and Diovan for hypertension, as well as generics through its Sandoz subsidiary. Novartis has been a full member of major industry associations including EFPIA, BIO, IFPMA, and PhRMA. The company's legacy is also tied to environmental and health controversies, notably the Toms River cancer cluster linked to a former Ciba-Geigy plant, and the historical role of Sandoz in the development and marketing of LSD. Novartis divested its agrochemical business in 2000 to form Syngenta and spun off other units such as Ciba Specialty Chemicals. As of 2024, it is the third most valuable pharmaceutical company in Europe, after Novo Nordisk and Roche.

Did You Know?

• Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz, considered the largest corporate merger in history at that time.
• The name Novartis is based on the Latin terms novae artes (new skills).

Roots in Basel's Chemical Heritage

Long before the name Novartis existed, two Basel-based chemical houses were laying the groundwork for what would become one of the world's most powerful pharmaceutical entities. When Ciba-Geigy and Sandoz merged in March 1996, the deal was regarded as the largest corporate merger in history at the time, and the new entity took its name from the Latin novae artes, meaning new skills.

A Portfolio That Shapes Modern Medicine

Novartis's drug portfolio spans psychiatric care, oncology, cardiovascular health, and infectious disease, reflecting the combined research heritage of its two predecessor companies. Among its most recognizable products are clozapine (marketed as Clozaril), the anticonvulsant carbamazepine (Tegretol), the blood-pressure agent valsartan (Diovan), and the landmark cancer drug imatinib mesylate, known as Gleevec or Glivec. The company also produces cyclosporine (Neoral/Sandimmune) for organ-transplant patients, the aromatase inhibitor letrozole (Femara), the antifungal terbinafine (Lamisil), and the iron-chelation agent deferasirox (Exjade). Over time, certain brands have changed hands or production arrangements: diclofenac (Voltaren) was sold to GlaxoSmithKline in a 2015 deal, and methylphenidate (Ritalin) has been produced by the Sandoz division since 2023. The Sandoz name itself was resurrected in 2003 when Novartis consolidated its generic-drug operations into a single subsidiary, restoring a brand that had been dormant for three years after the original merger.

Corporate Metamorphosis and Industry Standing

In the years following its 1996 birth, Novartis underwent significant structural changes as it shed non-core assets and sharpened its pharmaceutical focus. The most consequential divestiture came in 2000, when the company spun off its agrochemical and genetically modified crops division into Syngenta, a new entity created in partnership with AstraZeneca, which simultaneously divested its own agrochemical business. Other Ciba-Geigy and Sandoz operations were either sold outright or spun off as independent companies, including Ciba Specialty Chemicals. Novartis has also pursued a series of acquisitions to strengthen its core pharmaceutical and biotechnology businesses. Today the company ranks as the eighth-largest pharmaceutical firm globally by revenue and holds the position of the third most valuable pharmaceutical company in Europe, trailing only Novo Nordisk and Roche. It maintains full membership in several major industry bodies, including EFPIA, BIO, IFPMA, and PhRMA, underscoring its deep integration into both European and American pharmaceutical policy circles.

The Toms River Shadow

Novartis's corporate history carries a persistent environmental and public-health controversy rooted in its predecessor Ciba-Geigy's operations in Toms River, New Jersey. The area had already been designated a U.S. The plant finally ceased operations in 1996. A subsequent study covering 1996 to 2000 found that while cancer cases still exceeded expectations, rates had dropped significantly and the difference was no longer statistically significant compared to statewide norms. Since then, the Toms River water system has undergone the most rigorous water testing in New Jersey and is considered safe. The 2014 Pulitzer Prize-winning book Toms River: A Story of Science and Salvation by Dan Fagin examined the industrial pollution issue in depth.

Gallery